跳至主要内容
临床试验/PACTR201705002287258
PACTR201705002287258已完成未知

Effectiveness of a Cucumis sativus extract versus Glucosamine-Chondroitin used as placebo in the management of osteoarthritis: a randomized controlled trials

未提供0 个研究点目标入组 150 人开始时间: 2017年5月11日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
40 Year(s) 至 75 Year(s)(—)
性别
All

入选标准

  • ¿ Ambulatory, 40¿75 years of age, with a BMI of 18 to 30 kg/m2
  • ¿ Females of childbearing age must agree to use a medically approved form of birth control and have a negative urine pregnancy test result throughout the study
  • ¿ Female subjects of limited to no childbearing potential must be amenorrheic for at least 1 year or have had a hysterectomy, a bilateral oophorectomy, or both
  • ¿ Unilateral or bilateral OA of the knee for greater than 3 months plus a Kellgren and Lawrence radiographic grade of 2 or 3
  • ¿ VAS score during knee movement between 40¿70 mm after 7 day withdrawal of excluded medications
  • ¿ LFI score between 6¿10 points after 7 day withdrawal of excluded medications
  • ¿ Clinical laboratory results that are within normal range or considered not clinically significant by the Principal Investigator
  • ¿ Be willing to participate in all scheduled visits, tests, and other trial procedures according to the clinical protocol
  • ¿ Be willing to refrain from taking ibuprofen, aspirin or other NSAIDS, or any other pain reliever (OTC or prescription) during the entire trial other than acetaminophen (paracetamol) as rescue medication
  • ¿ Provide a signed and dated informed consent indicating that the subject has been informed of all pertinent aspects and possible risks associated with participation in the trial

排除标准

  • ¿ History of hypersensitivity to the rescue medication or any of the products used in the study
  • ¿ History of hypersensitivity to eggs, chicken or fowl, or shellfish
  • ¿ History of inflammatory arthropathy, severe RA, OA (VAS score greater than 70), or Systemic Lupus Erythematosus
  • ¿ Hyperuricemia (>440 ¿mol/L), past history of gout, or both
  • ¿ Anticipation of surgery within the next 4 months
  • ¿ Recent injury in the target knee (past 4 months)
  • ¿ History of use for corticosteroid, indomethacin, glucosamine & chondroitin within 3 months of Visit 2; intra-articular treatments, including injections of corticosteroid or hyaluronic acid; consumption of Omega 3 fatty acids dietary supplements within 6 months preceding the treatment period (a 2-week washout period is allowed for subjects taking omega 3 fatty acid supplements)
  • ¿ History of congestive heart failure
  • ¿ Anticipated problems with product consumption
  • ¿ Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic diseases, or malignancies within the last 5 years
  • ¿ High alcohol intake (>2 standard drinks per day) or use of recreational drugs (e.g., cocaine, methamphetamine, marijuana, etc.)
  • ¿ Females who are pregnant or lactating or planning to become pregnant
  • ¿ History of any mental illness that might impair the ability of subjects to provide a written informed consent
  • ¿ Consumed acetaminophen (paracetamol), ibuprofen, aspirin or other NSAIDS, or any other pain reliever (OTC or prescription), or any natural health product, (excluding vitamins) within 7 days of first visit
  • ¿ Participation in any clinical trials within 30 days prior to first visit

研究者

发起方
未提供

相似试验

Cucumis sativus extract | 临床试验